Company intelligence / Profile preview
Galux
Seoul, South Koreagalux.co.kr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Galux has achieved a significant milestone by demonstrating that its proprietary AI platform can successfully design de novo antibodies with high specificity and affinity against six diverse therapeutic targets. Its lead molecules have shown binding affinities comparable to or better than established drugs like atezolizumab in preclinical assays. The technology is validated through multiple industry and academic collaborations but there are no reported clinical trial results yet.
- Therapeutic areas
- OncologyMetabolic DisordersImmunology
- Modalities
- AntibodyPeptidesSmall moleculeProtein
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Validated through at least fifteen industry and academic collaborations; specific partners not named in public sources as of June 2025.
Beyond the preview
Go deeper on Galux.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galux.